INTRODUCTION AND OBJECTIVES: Treatment planning for adrenal tumors depends on a variety of qualitative and quantitative data, including tumor nature and anatomy, as well as the experience of the operating surgeon. Here, we have developed and propose a scoring system for adrenal masses designated as the A.D.R.E.N.A.L Score, to quantify the nature and anatomical characteristics of adrenal masses based on endocrinological assessment, computerized tomography and patient habitus.
METHODS: The A.D.R.E.N.A.L score consists of 7 components including (A)ldosterone/cortisol/catecholamine secretion or suspicion of malignancy based on endocrinological and radiological study, (D)imension (tumor size as the maximal diameter), (R)elationship to adjacent organs, (E)nhancement on computerized tomography, (N)earness of the tumor to major vessels, (A)dipose (patient habitus as body mass index), and a combination of two (L)ocation descriptors [anterior (a) or posterior (p), left (L) or right (R)]. The A.D.R.E.N.A.L score was applied to 345 cases, including 212 laparoscopic retroperitoneal adrenalectomy cases and 105 robotic retroperitoneal adrenalectomy cases and 28 robotic transperitoneal adrenalectomy cases.
RESULTS: For all three series, the A.D.R.E.N.A.L score accurately classified the complexity of cases in the above three series as evidenced by the positive correlation between the A.D.R.E.-N.A.L score and surgical outcomes including the operative time and estimated blood loss, while BMI or tumor size did not as independent risk factor. CONCLUSIONS: Standardized evaluation of an adrenal tumor is essential for individualized patient preparation, surgical planning and postoperative care which translate to patient safety and cost-effectiveness. The A.D.R.E.N.A.L score is a reproducible classification system based on endocrinological, oncological and anatomical characteristics of adrenal masses. This novel scoring system of adrenal masses may provide a common reference for the decision making of both endocrinologist and urologist, assessment of the surgical risks, patient safetyguided designing of adrenalectomy training programs, and stratified analysis and comparisons of adrenal surgeries within a single or among multiple institutions. INTRODUCTION AND OBJECTIVES: Partial Adrenalectomy (PA) has dramatically changed the treatment of patients affected by pathologies that affect both adrenal glands. Currently, evidences regarding the use of PA to treat primary macronodular adrenal hyperplasia(PMAH) are limited, including a small number of cases described as part of cohorts related to a variety of adrenal gland tumors. To date, the outcomes of this surgical treatment on hypercortisolism control is not known. In order to overcome the hormonal replacement caveats while minimizing the risks of hypercortisolism relapse, we performed a series of simultaneous total adrenalectomy of largest adrenal gland and contra-lateral partial adrenalectomy(adrenal sparing surgery) in patients with PMAH.
METHODS: Ten patients diagnosed with PMAH were treated surgically with adrenal sparing surgery. Primary endpoint was hypercortisolism remission, considered when patients had physiologic cortisol levels (5-25 mg/L) without hormonal reposition. Adrenal insufficiency and latent adrenal insufficiency were defined when oral hydrocortisone reposition was needed, with the dose of > 0,2 mg/kg/day and ¼ 0,2 mg/kg/day, respectively.Secondary endpoints were clinical and metabolic parameters improvement. Body mass index (BMI), blood pressure, cholesterol, lipid and glucose levels, were measured before and 12 months after the procedure. Medications to control comorbidities were also assessed and compared.
RESULTS: There were no intra-operative complications and average operation time was 189 AE 34 minutes. Median hospitalization period was 7,5 days and one patient needed surgical hematoma drainage. With a median follow-up of 24 months (range: 13 to 63 months), 40% of the cohort had complete hypercortisolism remission, 20% persisted with latent adrenal insufficiency and 40% with adrenal insufficiency. Hypercortisolism recurrence was not observed. Median systolic/diastolic blood pressures were 155/95 before and 123/80 after the procedure (p < 0,001). Median number of medications to control blood hypertension diminished from 3 to 1(p < 0,001). There was no significant change in cholesterol, lipid and glucose blood levels as well as the number of diabetes and lipid lowering medications. Median BMI decreased from 31,7 AE 7,8 to 28,4 AE 4,7(p ¼ 0.05).
CONCLUSIONS: An early assessment revealed that adrenal sparing surgery is a feasible procedure to treat patients affected by Vol. 197, No. 4S, Supplement, Saturday, May 13, 2017 THE JOURNAL OF UROLOGY â e477 PMAH, providing hypercortisolism remission and potentially avoiding the drawbacks of lifetime corticosteroids replacement.
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CLINICAL OUTCOME OF LAPAROSCOPIC ADRENALECTOMY IN SUB CLINICAL CUSHING SYNDROME; IS SURGICAL REMOVAL BETTER OR NOT?
Miki Fuse*, Shinichi Sakamoto, Kodai Sato, Takaaki Tamura, Akinori Takei, Satoshi Yamamoto, Yusuke Imamura, Koji Kawamura, Takashi Imamoto, Akira Komiya, Tomohiko Ichikawa, Chiba, Japan INTRODUCTION AND OBJECTIVES: Although no definitive surgical guide line exist in Sub-clinical Cushing Syndrome: SCS, surgical resection is considered based on the presence of hyper tension (HT), diabetes mellitus (DM) and hyper lipidemia (HL). Cortisole(CS) level > 3mg/dL after use of 1mg dexamethasone(Dex) was the U.S. guideline of SCS, while >1.8mg/dL in Japanese guideline. In this analysis, we have studied the clinical benefit of surgically removal in SCS tumor, especially patients with gray zone(between US and Japanese guideline);1.8 CS<3.0mg/dL after Dex 1mg treatment.
METHODS: Total of 112 patients diagnosed as SCS between 1997 and 2015 were included in this study. 94 patients underwent surgical adrenalectomy and 18 patients were none surgically observed. Clinical outcome such as HT, DM, HL and body mass index(BMI) were retrospectively analyzed. All the surgical adrenalectomies were performed by retroperitoneal laparoscopic adrenalectomy.
RESULTS: Median age was 65 years. Median tumor diameters were 30 mm. Significant improvement in HT (P<.0001), HbA1c (P¼0.016) and BMI (P¼0.0018) were observed in overall surgically removed SCS patients. Significant improvements in HT (P¼0.034) and BMI (P¼0.042) were also observed in 1.8 CS<3.0mg/dL group after surgery. However, clinical improvement were more evident in !3.0mg/ dL group, such as HT (P¼0.0002), HbA1c (P¼0.028) and HDL-C(P¼0.046), while no clinical improvement were observed in 1.8mg/dL groups. Although not reached statistical significance, surgical removal groups tends to show the reduction in prescribed drugs compare to none surgical groups(drugs related to DM 23 vs 10% p¼0.073, HT 37 vs 11% P¼0.078 and HL 43% vs 11% P¼0.282).
CONCLUSIONS: The current data showed that surgically removal of SCS tumor mediated significant improvements in the clinical symptoms. Based on expected clinical benefit,the gray zone SCS patients; 1.8 CS<3.0mg/dL after Dex 1mg treatment may also be a optimal candidate for laparoscopic adrenalectomy.
INTRODUCTION AND OBJECTIVES: Acquired adrenal insufficiency is a risk of unilateral adrenalectomy, performed either to remove a functional tumor or a gland with suspicion of cancer. All patients with evidence of a cortisol-secreting tumor receive a steroid taper in the first weeks after surgery, but some patients require an extended course of cortisol supplementation. Our objective was to determine the incidence of adrenal insufficiency at 30 days and at 1 year, as identified by requiring exogenous hormones to treat symptoms or abnormal laboratory values.
METHODS: A retrospective review was performed for all unilateral adrenalectomies at our institution from 2008-2016. Patient characteristics such as age and gender were recorded as risk factors, and surgical parameters such as laterality and pathology result, as well as tumor functionality were recorded. Logistic regression was used to determine which factors were associated with adrenal insufficiency as measured by cortisol supplementation at 30 days and at 1 year.
RESULTS: There were 115 unilateral adrenalectomies performed; 102 were laparoscopic and 13 were open. 62% of these were left-sided. Mean patient age was 56 and 64% of patients were female. 57 patients (50%) had biochemical evidence of a functional tumor prior to surgery. 9 patients (7.8%) required cortisol supplementation 30 days after surgery, and only 1 of these patients still required steroids (0.9%) at 1 year. All of these patients had signs and symptoms of hypercortisolism prior to adrenalectomy. Patients with a functional tumor were significantly more like to develop adrenal insufficiency (16%) at 30 days than those with a nonfunctional tumor (0%, p<0.005). Of the 9 patients requiring supplementation, 7 had adrenal cortical adenomas and 2 had adrenal hyperplasia. Gender was the only significant patient risk factor that predicted adrenal insufficiency at 30 days; (12% of females, 0% of males, p<0.05).
CONCLUSIONS: The incidence of adrenal insufficiency following unilateral adrenalectomy is low. Most patients who require hormone supplementation 30 days following surgery are able to wean off this requirement by 1 year. These data may help provide reassurance to patients undergoing adrenalectomy concerned regarding losing a functioning adrenal gland. Tumor functional status and female gender were significant predictors of adrenal insufficiency at 30 days. A larger sample size would likely be necessary to identify other significant predictors given the low incidence of insufficiency.
